<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854215</url>
  </required_header>
  <id_info>
    <org_study_id>15GENF03</org_study_id>
    <nct_id>NCT02854215</nct_id>
  </id_info>
  <brief_title>Cost Utility of Radical Surgery in Ovarian Cancer</brief_title>
  <acronym>CURSOC</acronym>
  <official_title>Cost Utility of Radical Surgery in Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the medico-economic impact of adherence to INCa
      (National Cancer Institute) guidelines in ovarian cancer surgery by assessment of outcome in
      cost per Quality Adjusted Life Years (QALY).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, comparative and non-randomized study designed to
      investigate the medico-economic impact of adherence to INCa guidelines in ovarian cancer
      surgery by assessment of outcome in cost per Quality Adjusted Life Years (QALY).

      A cost-utility study will be performed. It will primarily aim to assess the Incremental
      Cost-Utility Ratio (ICUR) at 3 years of the two treatment strategies of ovarian cancer
      surgery: adherence to INCa quality indicators versus non-adherence to INCa quality
      indicators.

      Consecutive patients with stage IIIC and IV ovarian, tubal, and primary peritoneal
      malignancies will be recruited in different health care institutions, including comprehensive
      cancer centers, university hospitals and private hospitals.

      Evaluation of adherence to quality indicators will be assessed retrospectively (once patients
      have completed the treatment) by two independent experts.

      200 patients will be included over a period of 2 years and will be followed for a 3 years
      period after treatment (every 4 months the first two years and then every 6 months).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cost-utility study</measure>
    <time_frame>5 years and 6 months</time_frame>
    <description>The primary endpoint is defined as cost per Quality-Adjusted Life Year (QALY) at 3 years. Patient utilities will be obtained from the EuroQoL 5D-3L questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of institutions adherent to INCa quality indicators</measure>
    <time_frame>2 years and 6 months</time_frame>
    <description>The rate of institutions adherent to INCa quality indicators corresponds to the number of institutions adherent to INCa quality indicators among the total number of institutions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients &quot;adherent&quot; to INCa quality indicators</measure>
    <time_frame>2 years and 6 months</time_frame>
    <description>The rate of patients &quot;adherent&quot; to INCa quality indicators corresponds to the number of patients adherent to INCa quality indicators among the total number of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 years and 6 months</time_frame>
    <description>The quality of life will be evaluated according to the QLQ-C30, QLQ-0V28 and the EQ-5D-3L questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Budgetary impact on the health insurance budget of these INCa quality indicators on the care management of ovarian cancer patients</measure>
    <time_frame>5 years and 6 months</time_frame>
    <description>Budgetary impact on the health insurance budget of these INCa quality indicators on the care management of ovarian cancer patients using costs data collected from the French insurance databases, Medical Information Departments of each participating centers and from patients' questionnaires (treatment costs, other induced costs and avoided costs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>5 years and 6 months</time_frame>
    <description>Progression Free Survival is defined as the time from inclusion until progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years and 6 months</time_frame>
    <description>Overall Survival is defined as the time from inclusion until death from any cause or last follow-up news (censored data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>5 years and 6 months</time_frame>
    <description>Morbidity will be assessed through recording of adverse events using NCI-CTCAE toxicity classification and vital signs measurement.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Ovarian cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient undergoing primary surgery for a newly diagnosed ovarian, tubal or peritoneal malignancies; Stage IIIc or IVa with extrapelvic carcinomatosis according to the International Federation of Gynecology and Obstetrics classification 2014</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of additional data with questionnaires</intervention_name>
    <description>questionnaires for quality of life measurements: QLQC30; QLQ-OV28
questionnaires for medico-economic purposes: ADL (activities of daily living); IADL (instrumental activities of daily living); EQ-5D3L; absenteeism questionnaire.
These questionnaires will be completed during the study time (5 or 6 times during the treatment, next every 4 months during the first two years and then every 6 months during the third year of follow-up).</description>
    <arm_group_label>Ovarian cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Woman with age ≥ 18 years.

          -  2. Newly diagnosed ovarian, tubal or peritoneal malignancies.

          -  3. Epithelial histology.

          -  4. Stage IIIC or IVA with extrapelvic carcinomatosis according to FIGO classification
             2014.

          -  5. Patients undergoing primary surgery or neoadjuvant chemotherapy.

          -  6. Performance Status ≤ 2.

          -  7. Patient affiliated to a Social Health Insurance in France.

          -  8. Patient information and informed consent form signed prior to any study specific
             procedures.

        Exclusion Criteria:

          -  1. Benign or borderline tumors.

          -  2. Patients with extra-abdominal disease, except for pleural effusion with positive
             cytology.

          -  3. Other malignancy diagnosed in the previous 5 years except skin cancer (other than
             melanoma).

          -  4. Any psychological, familial, geographic or social situation, according to the
             judgment of investigator, potentially preventing the provision of informed consent or
             compliance to study procedure.

          -  5. Patient who has forfeited his/her freedom by administrative or legal award or who
             is under guardianship.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alejandra MARTINEZ, PhD</last_name>
    <phone>+33 531 15 51 00</phone>
    <email>martinez.alejandra@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUYON Frederic</last_name>
      <phone>05 56 33 78 30</phone>
      <email>f.guyon@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BOURDEL Nicolas</last_name>
      <phone>04 73 75 06 79</phone>
      <email>nbourdel@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>POMEL Christophe</last_name>
      <email>christophe.pomel@cjp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAMBAUDIE Eric</last_name>
      <phone>04 91 22 35 32</phone>
      <email>lambaudiee@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Regional Du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COLOMBO Pierre Emmanuel</last_name>
      <phone>04 67 61 31 50</phone>
      <email>pierre-emmanuel.colombo@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice LECURU</last_name>
      <phone>01 56 09 35 84</phone>
      <email>fabrice.lecuru@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>POUGET Nicolas</last_name>
      <phone>01 56 24 59 14</phone>
      <email>nicolas.pouget@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GERTYCH Witold</last_name>
      <phone>04 78 86 41 78</phone>
      <email>witold.gertych@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BAKRIN Naoual</last_name>
      <phone>04 78 86 23 71</phone>
      <email>naoual.bakrin@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste de La Sagesse</name>
      <address>
        <city>Rennes</city>
        <zip>35043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BLANCHOT Jérôme</last_name>
      <phone>02 99 85 75 14</phone>
      <email>jblanchot@lasagesse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARTINEZ Alejandra</last_name>
      <phone>05 31 15 53 66</phone>
      <email>martinez.alejandra@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

